title: Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
abstract: Antiestrogen therapy of ductal carcinoma in situ (DCIS) has become a more common option in reducing risk of developing invasive cancer. Previously, estrogen receptor alpha (ER-alpha) was evaluated as the only predictive factor. Immunohistochemical staining was performed for ER-alpha, estrogen receptor ER-beta, progesterone receptor (PR), pS2 and her-2/neu in 59 cases of ductal carcinoma in situ (DCIS). We observed a positive correlation between the expression of ER-alpha (p=0.003), PR (p<0.001) and histopathological grading. Of the DCIS, 61.5% of ER-beta positive (p=0.046) and 35.5% of PR positive samples showed a coexpression with pS2, whereas 72.1% of pS2 negative DCIS were also negative for ER-beta and 92.9% of PR negative DCIS were negative for pS2 (p=0.012). In contrast, 50.0% of her-2/neu negative DCIS expressed ER-beta receptor (p=0.052). We propose that there are subpopulations of DCIS which can be described by distinct endocrine-associated expression patterns.
authors.affiliation: Department of Obstetrics and Gynecology, University of Hospital of Muenster, Germany. achim.rody@em.uni-frankfurt.de
authors.forename: Achim
authors.initials: A
authors.lastname: Rody
authors.forename: Raihanatou
authors.initials: R
authors.lastname: Diallo
authors.forename: Christopher
authors.initials: C
authors.lastname: Poremba
authors.forename: Regina
authors.initials: R
authors.lastname: Speich
authors.forename: Pia
authors.initials: P
authors.lastname: Wuelfing
authors.forename: Stephen
authors.initials: S
authors.lastname: Kissler
authors.forename: Christine
authors.initials: C
authors.lastname: Solbach
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kiesel
authors.forename: Christian
authors.initials: C
authors.lastname: Jackisch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D053766:Presenilin-2; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D008565:Membrane Proteins; D053766:Presenilin-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; C508861:PSEN2 protein, human